Health Robotics' CytoCare Continues European Expansion With Grifols and Vall d'Hebron University Hospital

BOZEN, Sud-Tirol, Italy, July 20, 2010 - Health Robotics today announced that it recently signed agreements to
grant exclusive CytoCare distribution rights in Spain and Portugal to
world-leading IV Therapy company Grifols S.A., and to install the first-ever
Cancer Therapy Robot in Spain at Vall d'Hebron University Hospital in
Barcelona in November 2010.

"We are very excited to have been selected by Health Robotics as their
long-term exclusive CytoCare partner in Spain and Portugal, adding the Cancer
Therapy Robot in our core Iberian peninsula market to our prior i.v.STATION
distribution rights. CytoCare, the world's first and only robotic system
designed for the safe and sterile preparation of patient-specific hazardous
IV Admixtures, represents an ideal complement to our other market-leading
Pharmacy Automation products. Vall d'Hebron University Hospital has
demonstrated a long trajectory of innovation, utilizing new technologies to
achieve excellent peer-reviewed and published efficiency and medication
safety results, with prestigious awards such as Best European Pharmacy
Management, ESADE's Management Innovation, and finally the Best Health Care
Ideas in 2009", stated Xavier Guix, Vice President of Marketing for Grifols'
Hospital System Division".

"It is very exciting to expand our i.v.STATION relationship at such a
prestigious hospital as Vall d'Hebron University Hospital, with its
world-renowned cancer research program and the well-documented scientific
publications by Dr. Josep Monterde and his team of scientists and
pharmacists; we feel rewarded with this new contract after 1.000 Bed Bolzano
General Hospital hosted an inspection team from Vall d'Hebron University
Hospital in order to ascertain CytoCare's speed, flexibility, and safety in
comparison with other IV Robotics companies, and demonstrating that CytoCare
handled 70% of Chemo IV doses within a 4 hour time-window. Additionally,
Grifols is the perfect fit for CytoCare in Spain and Portugal due to its
well-established distribution channels, commitment to patient safety, its
company stability and superior market footprint, and finally its world-class
service infrastructure. In addition to the obvious success in expanding our
partnership with Grifols and receiving a repeat endorsement from an existing
Health Robotics' partner, I'm very pleased that this new contract symbolizes
the first CytoCare installation in Spain, and the eight European Union member
country to embrace CytoCare for its Oncology Therapy Compounding needs",
stated Werner Rainer, Health Robotics' CEO.

About Vall d'Hebron University Hospital:

Vall d'Hebron University Hospital, the leading hospital complex in
Catalonia and one of the largest in Spain, is comprised of four large centers
- the General Area, the Maternity and Children's Area, the Traumatology and
Rehabilitation Area and the Outpatient Surgery Unit (Pere Virgili Health Care
Park) - which cover almost all the medical and surgical specialties. The Vall
d'Hebron University Hospital, with a total of more than 1400 beds, also house
various teaching centers, public health care enterprises, research centers,
laboratories and other complementary facilities. www.vhebron.net/

About Grifols S.A.:

Grifols International is a Spain-based company engaged in the healthcare
sector and is listed on Ibex-35 stock market. Grifols is involved in the
research, development, manufacturing and marketing of plasma derivates, IV
therapy solutions, enteral and parenteral nutrition, diagnostic systems,
pharmacy automation, and medical materials and devices. Founded in 1940,
Grifols currently operates in 90 countries with more than 6.000 employees, 26
subsidiaries with combined gross revenues over EUR800 million, and a EUR3
billion market capitalization. For more information, please visit
www.grifols.com

About Health Robotics:

Health Robotics is the undisputed global leading supplier of
life-critical intra-venous medication robots, providing healthcare facilities
in 5 continents with robotics technology and software automation solutions
deployed utilizing virtual high-availability technology. Its world-leading
solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs],
i.v.SOFT(TM) [workflow engine for manual compounding], and TPNstation(TM)
[totally-automated parenteral nutrition] have and will greatly contribute to
ease hospitals' growing pressures to improve patient safety, increase
throughput and contain costs. Through the effective and efficient production
of sterile, accurate, tamper-evident and ready-to-administer IVs, Health
Robotics' solutions help hospitals eliminate life-threatening drug-exchange
errors, decrease other therapy oversights and sterility risks, work more
efficiently, reduce waste and controlled substances' diversion, and diminish
the gap between rising patient volume/acuity and scarce nursing and pharmacy
staff.

For more company information including a corporate video, please visit
www.health-robotics.com/en/about-health-robotics/. For additional
information, please contact:

    Health Robotics S.r.l.
    Claudia Flaim, Marketing Coordinator
    Phone: +39-0471-200-372
    flaim@health-robotics.com

Health Robotics S.r.l., Claudia Flaim, Marketing Coordinator, Phone: +39-0471-200-372, flaim at health-robotics.com